Image credit- stockvault.net
The Korean government has approved Ono Pharma Korea and Bristol-Myers Squibb Korea to sell Opdivo (nivolumab)-Yervoy (ipilimumab) combination therapy as the first-line immunotherapy to treat renal cell carcinoma (RCC).
The approval is based on a clinical trial called CheckMate-214, which evaluated the Opdivo-Yervoy combo in patients with moderate- and high-risk advanced RCC who did not have any treatment experience.
The study showed the combined therapy proved effective in achieving improved survival compared to sunitinib (under trade name Sutent by Pfizer), regardless of PD-L1 (programmed death-ligand 1) expression.
